These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19551691)

  • 21. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination.
    Larsson LI
    Arch Ophthalmol; 2001 Apr; 119(4):492-5. PubMed ID: 11296014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
    Schadlu R; Maus TL; Nau CB; Brubaker RF
    Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.
    Chen MJ; Chou JC; Hsu WM; Liu JH
    J Chin Med Assoc; 2003 May; 66(5):276-81. PubMed ID: 12908569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
    David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
    Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
    Adkins JC; Balfour JA
    Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brimonidine tartrate for the treatment of glaucoma.
    Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
    Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits.
    Reitsamer HA; Posey M; Kiel JW
    Exp Eye Res; 2006 Mar; 82(3):405-15. PubMed ID: 16198336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
    Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
    Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of brimonidine ingestion on cardiovascular responses and renal function in conscious dogs.
    Suwanwipat S; Buranakarl C; Chaiyabutr N
    Vet Res Commun; 2007 Apr; 31(3):323-34. PubMed ID: 17195055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
    Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
    Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
    Carlsson AM; Chauhan BC; Lee AA; Leblanc RP
    Am J Ophthalmol; 1999 Dec; 128(6):697-701. PubMed ID: 10612505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(3):113-120. PubMed ID: 31393455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
    Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
    Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.
    Wheeler LA; Woldemussie E
    Eur J Ophthalmol; 2001; 11 Suppl 2():S30-5. PubMed ID: 11592528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys. A species difference.
    Burke J; Kharlamb A; Shan T; Runde E; Padillo E; Manlapaz C; Wheeler L
    Ann N Y Acad Sci; 1995 Jul; 763():78-95. PubMed ID: 7677389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
    Katz LJ
    Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brimonidine (Alphagan): a clinical profile four years after launch.
    David R
    Eur J Ophthalmol; 2001; 11 Suppl 2():S72-7. PubMed ID: 11592536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.